Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/2C-X/Immunology & Inflammation

2C-X for Immunology & Inflammation

1 paper and 0 clinical trials exploring 2c-x as a treatment for immunology & inflammation.

CompoundPhenethylamine

2C-X

2C-X denotes a family of synthetic phenethylamine psychedelics defined by a 2,5-dimethoxyphenethylamine scaffold. 2C-B is the best-studied member, with emerging controlled human data benchmarking it against psilocybin and MDMA.

Full 2C-X profile
IndicationOver 264 million people worldwide suffer from depression, with a significant subset experiencing related inflammatory conditions.

Immunology & Inflammation

Recent research highlights the potential of psychedelics, particularly psilocybin and MDMA, in modulating immune responses and inflammation, shedding light on their therapeutic implications for mood disorders and other immune-related conditions. Studies are beginning to uncover the mechanisms through which these compounds exert anti-inflammatory effects and promote neuroplasticity, particularly in the context of major depressive disorder (MDD).

Full Immunology & Inflammation profile

Academic Research

1 paper
Open Accessindividual

Structure-Activity Relationship Analysis of Psychedelics in a Rat Model of Asthma Reveals the Anti-Inflammatory Pharmacophore

This rat study (n=52) investigated structure−activity relationships between 5-HT2A receptor agonists within a novel rat model of allergic asthma and identified that phenylalkylamine structure 2,5-dimethoxyphenethylamine (2C-H) mediated anti-inflammatory activity. There was no apparent correlation between behavioral and anti-inflammatory effects, which indicates distinct structural features of 5-HT2A receptor activity that can be utilized for the development of asthma treatments independent of subjective psychedelic effects.

Published
June 4, 2020
Journal
ACS Pharmacology and Translational Science
Authors
Flanagan, T. W., Billac, G. B., Landry, A. N., Sebastian, M. N., Cormier, S. A., Nichols, C. D.

Clinical Trials

0 trials

No clinical trials have been tagged with both 2C-X and Immunology & Inflammation yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all 2C-X papers Search all Immunology & Inflammation trials Full 2C-X profile Full Immunology & Inflammation profile